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OBJECTIVES: Eligibility criteria for government-funded chronic
hepatitis C treatment in Australia stipulate that patients must
have biopsy-proven evidence of liver damage. This was initially
incorporated in an effort to limit treatment to those patients who
were most likely to achieve the greatest clinical beneﬁt, namely
patients with more progressed disease who are closer to poor
health states. However, recent evidence acknowledges signiﬁcant
quality of life impairments in patients with histologically mild
disease and suggests that earlier initiation of treatment may be
more cost-effective than previously thought. With no ran-
domised controlled trials that directly compare “early” versus
“later” treatment of patients with pegylated interferon alpha-2b
plus ribavirin, the aim of this study was to model the incremen-
tal cost-effectiveness of treatment in subjects with mild versus
more advanced disease. METHODS: A cost-utility Markov
model was developed to compare “earlier” versus “later” treat-
ment, where “earlier” treatment commences in the mild health
state or after progression to the moderate health state, and
“later” treatment commences after histological evidence of sig-
niﬁcant hepatic ﬁbrosis. The analysis was conducted from the
perspective of the Australian health care system using data from
an international randomised controlled trial in chronic hepatitis
C. RESULTS: The incremental cost-effectiveness ratio (ICER)
ranged from $14,047 to $17,208 per quality adjusted life year
(QALY) using different sets of published utility weights and tran-
sition probabilities. For patients infected with viral genotypes 2
or 3 the ICER is $9584/QALY, while for genotypes 1, 4, 5, or 6
the ICER is $19,297/QALY. Sensitivity analyses based on alter-
native inputs yield ICERs ranging from $1034 to $22,277/
QALY. CONCLUSIONS: Treatment with pegylated interferon
alpha-2b plus ribavirin is universally cost-effective in patients
with mild chronic hepatitis C, regardless of hepatitis C virus
genotype. Withholding treatment until a patient exhibits histo-
logical evidence of liver damage is not justiﬁed from the current
analysis.
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OBJECTIVES: The growing emergence of bacterial resistance is
related to the overuse and misuse of antibiotics. The aim of this
study was to evaluate the prescribing of antibiotics by Mon-
tenegrian primary health care (PHC) practitioners in the treat-
ment of the most common infections. METHODS: We used the
computerised report that was extracted from the Information
system named “The Control of Distribution and Use of Drugs”
that has been established within The Republic Health Insurance
Fund since 2003. The report covered ATC code, generic name,
number of deﬁned daily doses that were prescribed during 2005
and the diagnoses of infections (International Classiﬁcation of
Diseases-ICD) for which antibiotics were prescribed. Our results
were expressed as number of DDD/1000 inhabitants/day
(DTID). RESULTS: The prescribing of antibiotics was highest
for the treatment of acute upper respirstory tract infections
(URTI, ICD codes J00-J04) (7.9 DDDs), acute bronchitis (J20)
(1.7 DTIDs) and cystitis (N30) (1.1 DTIDs). For the treatment
of URTI amoxicillin had the highest prevalence (2.7 DTIDs,
34%). Amoxicillin with clavulanic acid was the second drug (1.4
DTIDs, 17%) and narrow-spectrum penicillin V was the third
(0.8 DTIDs, 10%). Acute bronchitis was treated mostly by
macrolides azitromycin (0.4 DTIDs, 23%) and erythromycin
(0.3 DTIDs, 19%), followed by amoxicillin (0.3 DTIDs, 17%).
Sulfamethoxazole-trimethoprim was most common prescribed
antibiotic for the treatment of cystitis (0.4 DTIDs, 37%), cefalex-
ine was the second drug (0.3 DTIDs, 25%) and ciproﬂoxacin
(0.2 DTIDs, 15%) was the third. CONCLUSIONS: This survey
showed a slight tendency of Montenegrian PHC physicians to
more frequently prescribe wide-spectrum (and more expensive)
antibiotics. They also prescribed antibiotics in some diagnoses
where It was controversal and wasn’t supported with strong 
clinical evidence. Further studies about patterns of bacterial
resistance to antibiotics and pharmacoeconomic aspect of 
pharmacotherapy are needed to fully estimate is the prescribing
of antibiotics rational or not.
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